Articles from BioAge Labs, Inc.

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference.

Advancement of next-generation APJ agonists with discontinuation of azelaprag

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Goldman Sachs Second Annual “Year-Ahead” Catalyst Clinic on Thursday, December 19, 2024, 11–12 PM EST.

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity

Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with azelaprag monotherapy

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that Kristen Fortney, PhD, CEO and co-founder, will present at the Jefferies London Healthcare Conference, which takes place November 19–21, 2024.

RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the closing of its upsized initial public offering of 12,650,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,650,000 additional shares, at the initial public offering price of $18.00 per share. All of the shares were offered by BioAge.

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share. All of the shares are being offered by BioAge. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $198.0 million.

BioAge Labs, Inc. (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the appointment of Jean-Pierre Garnier, PhD, as Chair of the company’s Board of Directors. Garnier will succeed current Board Chair James Healy, MD, PhD, managing partner of Sofinnova Investments, who will remain on the Board.

BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced preclinical data for its lead product candidate azelaprag, an orally available small molecule agonist of the apelin receptor APJ, in combination with incretin agonists for the treatment of obesity. The data were presented in a talk by BioAge’s Chief Medical Officer and EVP-Research Paul Rubin, MD, at the American Diabetes Association's 84th Scientific Sessions. The conference, being held June 21–24 in Orlando, convenes more than 12,000 leading physicians, scientists, and health care professionals and features the latest scientific and therapeutic findings in diabetes.

BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the formation of its Scientific Advisory Board (SAB). The SAB is composed of world-renowned leaders with expertise spanning metabolic disease biology, obesity medicine, and clinical development of blockbuster therapeutics. The SAB will work closely with BioAge's leadership team to advance the company's pipeline of novel treatments for age-related chronic metabolic diseases into mid- and late-stage clinical development.

BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors.

BioAge Labs, Inc., (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced plans to initiate a Phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) co-administered with the GLP-1/GIP receptor agonist tirzepatide for treatment of obesity. BioAge plans to initiate the trial in mid-2024.

BioAge Labs, Inc., a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of BJ Sullivan, Ph.D., as Chief Strategy Officer. Sullivan is the first to hold the position at BioAge.

BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that the company will provide updates on the company's progress in novel target identification and drug development in the brain aging area at upcoming conferences in the US and UK.

BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that the company will host an online key opinion leader (KOL) event for analysts, investors, and other interested parties on its first-in-class apelin receptor agonist BGE-105. The event will be broadcast online on Wednesday, January 4, 2023 at 2:00 PM ET.

BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced positive Phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest.

BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it will present updates on its NLRP3 inhibitor program [link] at two upcoming conferences in the United States, Neurodegeneration Targets and the Inflammasome Therapeutics Summit, and at the BIO-Europe 2022 conference in Leipzig, Germany. BioAge is developing its novel, proprietary class of NLRP3 inhibitors, which have distinct structural and biological properties and include molecules that penetrate the blood–brain barrier, for neurodegenerative and neurosensory disorders associated with aging.

BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it has initiated a partnership agreement with Age Labs AS (“Age Labs”), a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records from the Nord-Trøndelag Health Study (HUNT) biobank collected from more than 100,000 Northern European volunteers over more than 25 years of aging, and apply machine learning methods to the resultant data to reveal the key molecular mechanisms of healthy human longevity. The agreement grants the Company exclusive access for the purpose of drug discovery to data generated by the partnership.

BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that Kristen Fortney, PhD, CEO and Co-Founder of BioAge, will lead a panel discussion at the BIO International Conference held June 13–16, 2022 in San Diego, California (“BIO 2022”).

BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that BioAge chief business officer (CBO) Peng Leong, PhD, MBA, has been appointed as the Company’s Head of Brain Aging.

BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it is developing a family of novel small-molecule NLRP3 inhibitors as therapeutics for inflammatory and age-related diseases. The inhibitors, BioAge’s first proprietary compounds, were created by leveraging the Company’s unique platform and in-house drug development expertise. The BioAge family of NLRP3 inhibitors has differentiated features including

BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that the first cohort has been dosed in a Phase 1b trial of BGE-105, a highly selective and potent small-molecule agonist of the apelin receptor APJ.

BioAge Labs, Inc., a biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced that its clinical-stage oral drug BGE-175 (asapiprant), which targets age-related immune deficiencies, protects aged mice from lethal infection with SARS-CoV-2, the virus that causes COVID-19. An article describing the findings was published today in the international scientific journal Nature [1].

BioAge Labs, Inc. (link), a clinical-stage biotechnology company and global leader in using artificial intelligence (AI) and machine learning (ML) to develop drugs that target the molecular causes of aging, today announced that the Company will participate in a panel discussion at the Truist Securities Life Sciences AI Symposium, the first of three investment banking corporate access events to which BioAge will contribute in the coming two months.

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO). Both officers are the first to hold their respective positions at BioAge.

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Rekha Hemrajani and Jason Coloma to the company’s board of directors.

BioAge Labs, Inc. a biotechnology company developing medications that target the molecular causes of aging to extend healthy human life, today announced that it has entered into an exclusive worldwide license agreement with Amgen, Inc. [Head Office: Thousand Oaks; CEO: Robert Bradway] to develop and commercialize Amgen’s clinical-stage APJ agonist, BGE-105 (named AMG 986 by Amgen) to ameliorate muscle aging. In older people, muscle aging causes loss of strength, mobility, and function, driving mortality and multiple age-related diseases and decreasing overall quality of life.